- |||||||||| Dificid (fidaxomicin) / Merck (MSD), Astellas, Zinplava (bezlotoxumab) / Merck (MSD)
Review, Journal: Clostridioides difficile infection in the allogeneic hematopoietic cell transplant recipient. (Pubmed Central) - Dec 11, 2023
In pediatric patients, vancomycin and metronidazole are still suggested as first-line therapy, but fidaxomicin will probably become standard in pediatrics in the near future. Because of insufficient safety data, fecal microbiota transplantation is not routinely recommended in HCT in spite of promising results for the management of recurrences in other populations.
- |||||||||| Dificid (fidaxomicin) / Merck (MSD), Astellas
Journal: Clostridioides difficile infections; new treatments and future perspectives. (Pubmed Central) - Nov 9, 2023
With current first-in-line antibiotic therapy options associated with high levels of recurrent CDI, the availability of new generation targeted therapeutics can really impact treatment success. There are still unknowns about the long-term implications of these new CDI therapeutics, but efforts to expand the CDI treatment toolbox can offer multiple solutions for clinicians to treat this multifaceted infectious disease to reduce patient suffering.
- |||||||||| Review, Journal: Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies. (Pubmed Central) - Oct 22, 2023
In the phase III PUNCH CD3 trial, RBX2660 also demonstrated high efficacy rates of 70.6% versus 57.5%...Other standardized microbiome-based therapies currently in the pipeline are VE303, RBX7455, and MET-2. Antibiotic neutralization strategies, vaccines, passive monoclonal antibodies, and drug repurposing are other therapeutic strategies being explored to treat C. difficile infection.
- |||||||||| vancomycin / Generic mfg., Dificid (fidaxomicin) / Merck (MSD), Astellas
Journal: Assessing the Impact of Two-Step Clostridioides difficile Testing at the Healthcare Facility Level. (Pubmed Central) - Oct 22, 2023
The parallel decrease in C. difficile-specific antibiotic use offers indirect reassurance against underdiagnosis of C. difficile infections still requiring treatment by clinician assessment. Similarly, the absence of any significant change in colectomy rates offers indirect reassurance against any rise in fulminant C. difficile requiring surgical management.
- |||||||||| Dificid (fidaxomicin) / Merck (MSD), Astellas
Review, Journal: Microbial ecology between Clostridioides difficile and gut microbiota. (Pubmed Central) - Oct 4, 2023
In addition, approaches to restoring the gut microbiota by using probioitcs and live biotherapeutic products (LBPs) are currently being studied to examine the effect on CDI. Further microbial ecological research on C. difficile and gut microbiota could lead to a better understanding of the pathogenesis and treatment of CDI.
- |||||||||| Dificid (fidaxomicin) / Merck (MSD), Astellas
Journal: Antisense inhibition of RNA polymerase ? subunit of Clostridioides difficile. (Pubmed Central) - Sep 29, 2023
Additionally, antisense inhibition of the C. difficile rpoA gene did not impact healthy microflora. We also propose a novel approach to manipulate gene expression in C. difficile without the need for established genetic tools.
- |||||||||| Dificid (fidaxomicin) / Merck (MSD), Astellas
Journal, HEOR: A cost-utility analysis of two Clostridioides difficile infection guideline treatment pathways. (Pubmed Central) - Sep 26, 2023
The different approaches experimented with in the destruction of C. difficile and treatment of CDI are evaluated. Compared with the NICE guideline, the ESCMID guideline recommendations for treating an index CDI represent the most cost-effective use of healthcare resources from the perspective of the UK National Health Service.
- |||||||||| Dificid (fidaxomicin) / Merck (MSD), Astellas, Rebyota (fecal microbiota, live-jslm) / Ferring
Journal: Patient Perception of Route of Rectal Administration of Live Biotherapeutic Product for Recurrent Clostridioides difficile Infection. (Pubmed Central) - Sep 7, 2023
Standard of care management includes the antibiotics, vancomycin and fidaxomicin, which frequently provide clinical response, but do not avoid recurrence of Clostridioides difficile infection (rCDI)...Group 1 consisted of LBP-recipients who had received RBL (REBYOTA) rectally as part of the Phase III PUNCH CD3 clinical trial...Many of these subjects (76%) expressed interest in finding out about new treatment options for rCDI. LBP-recipients and LBP-na
- |||||||||| Review, Journal: Clostridioides difficile resistance to antibiotics, including post-COVID-19 data. (Pubmed Central) - Aug 29, 2023
Resistance to erythromycin (>60-88%), rifampin (>23-55.0%), imipenem (0.6 to?>?78% in a clone), tigecycline (0-<5.0%), and fidaxomicin (0-2%) was also found...New approaches, including biotherapeutics (Rebyota), strains, antibiotics (ridinilazole and ibezapolstat), and monoclonal antibodies/cocktails merit further evaluation...Post-COVID-19 resistance should be separately presented. Some discrepancies between vancomycin and metronidazole results need to be clarified.
- |||||||||| Dificid (fidaxomicin) / Merck (MSD), Astellas, Zinplava (bezlotoxumab) / Merck (MSD)
Review, Journal: Therapeutics for Clostridioides difficile infection: molecules and microbes. (Pubmed Central) - Aug 22, 2023
There are now two FDA approved microbiome-based therapies or live biotherapeutics for prevention of recurrent CDI, for any recurrent CDI and not necessarily multiply recurrent C difficile. Fecal microbiota transplantation remains available in limited settings for recurrent CDI.
- |||||||||| Dificid (fidaxomicin) / Merck (MSD), Astellas
Journal: Clostridioides difficile Infection in Children: Recent Updates on Epidemiology, Diagnosis, Therapy. (Pubmed Central) - Aug 10, 2023
Recent advancements in our understanding of emerging epidemiologic trends and management of CDI unique to children are highlighted in this review. Despite encouraging therapeutic advancements, there remains a pressing need to optimize CDI therapy in children, particularly as it pertains to severe and recurrent disease.
- |||||||||| Dificid (fidaxomicin) / Merck (MSD), Astellas, Zinplava (bezlotoxumab) / Merck (MSD)
Journal: Prevention and treatment of C. difficile in cancer patients. (Pubmed Central) - Aug 1, 2023
Further studies are needed to provide robust recommendations for diagnosis, grading severity, and therapeutic management of CDI in cancer patients. Recurrences are particularly concerning due to subsequent exposition to CDI risk factors.
- |||||||||| Dificid (fidaxomicin) / Merck (MSD), Astellas
Case of Severe Multifactorial Diarrhea in the Setting of Clostridioides difficile; Infection and Lymphocytic Colitis Unresponsive to Budesonide (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_3590;
He received budesonide 9 mg QD for four weeks and prednisone 20 mg BID for two weeks without relief...He again received 14 days of PO vancomycin without symptom resolution...He was switched to IV Mg supplementation and was treated with fidaxomicin for recently positive C. diff...The elevated Chromogranin A is likely multifactorial in the setting of PPI use, CDI, inflammation from chronic diarrhea, and possibly autoimmune-related given bullous pemphigoid. Notably, Chromogranin should not be routinely checked in the workup of chronic diarrhea but was followed up due to significantly abnormal result.
- |||||||||| Dificid (fidaxomicin) / Merck (MSD), Astellas, Vistide (cidofovir) / Gilead, Mycamine (micafungin) / Astellas
A Case of Fulminant Liver Failure Secondary to Adenovirus in Kidney Transplant Patient (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_2964;
CAR T cells targeting virally infected cells remain in early pre-clinical testing but show promise in providing long-term control when anti-viral treatments fail. Prospective studies are needed to better understand the pathogenesis of HAdV infection and therapies.
- |||||||||| Rinvoq (upadacitinib) / AbbVie
Induction of Remission in TNF-Alpha Inhibitor Refractory Acute Severe Ulcerative Colitis With Upadacitinib: A Case Report (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_2704;
Case Description/ A 24-year-old man without past medical history presented to our clinic for recurrent bloody diarrhea following a mild colitis 8 months prior treated with oral ciprofloxacin/metronidazole...Induction with Upadacitinib 45 mg was administered after 5 days of oral vancomycin, 1 day of fidaxomicin, and a third dose of Infliximab failed to improve his symptoms...Upadacitinib has been shown to be a comparably safe treatment option as phase IIb and III induction and maintenance studies demonstrated lower rates of serious adverse events on induction compared to placebo with a slightly elevated risk of minor adverse events during maintenance including herpes zoster and nasopharyngitis. While further head-to-head studies are warranted, multiple network meta-analyses evaluating the comparative efficacy of UC treatments have positioned upadacitinib as the most effective induction and maintenance treatment for moderate-severe UC regardless of prior TNF-alpha inhibitor exposure.
- |||||||||| Dificid (fidaxomicin) / Merck (MSD), Astellas
Atypical Presentation of Metastatic Prostate CA Mistaken for Recurrent Clostridiodes difficile Infection (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_2488;
This course was later repeated with fidaxomicin again without much improvement...Therefore, this emphasizes the importance of clinical judgement and how there may be a role of endoscopic investigation in patients with atypical presentations for CDI. Figure: Figure A: Rectal nodularity under Narrow Band Imaging Figure B: Rectal nodularity under White Light
- |||||||||| Dificid (fidaxomicin) / Merck (MSD), Astellas
Recurrent Clostridioides difficile Infection Refractory to FMT (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_2192;
Patient was hospitalized for 2 weeks for CDI and treated with PO Vancomycin...Started on fidaxomicin and inpatient FMT performed...It is very rare to have rCDI following one FMT however there are even fewer cases that are refractory to two or more. Figure: Images from Colonoscopy A - pseudomembranous colitis
- |||||||||| Dificid (fidaxomicin) / Merck (MSD), Astellas
A Rare Case of Clostridioides difficile Enteritis in a Patient With Recurrent C. diff Status Post Loop Ileostomy (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_1796;
She had also received oral vancomycin, and Fidaxomicin in the past for prior C. diff infections...This patient had multiple risk factors for C.diff including age, multiple underlying co-morbidities, history of prior C.diff infection and history of altered intestinal anatomy. She responded well to fecal microbiota transplant which was delivered via upper endoscopy due to her altered anatomy.
- |||||||||| Dificid (fidaxomicin) / Merck (MSD), Astellas, Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma, Humira (adalimumab) / AbbVie
Clostridioides difficile Strikes Again (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_1663;
For the second or subsequent recurrence, recommendations are pulsed vancomycin for 2-4 months or vancomycin for ten days, followed by either fidaxomicin, rifaximin, or nitazoxanide...While on adalimumab therapy, he developed his first episode of CDI treated with vancomycin... As far as we are aware, this is the first case report of a patient developing symptomatic CDI while on fidaxomicin
- |||||||||| cisplatin / Generic mfg.
Cisplatin-Induced Recurrent Clostridium difficile Infection (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_701;
Treated with Fidaxomicin following the 3 consecutive chemotherapy cycles Adults with cancer had a 7%-14% higher incidence of Clostridium difficile infection (CDI) than the overall hospitalized population (1%-2%)...Every time a patient receiving antineoplastic treatment experiences diarrhea, C. difficile infection should be considered. Early therapy and prompt, appropriate diagnostic testing may prevent morbidity and death.
|
